Alpha Tau Medical Ltd. (NASDAQ:DRTS) on Sunday reported positive interim results from its U.S. REGAIN trial evaluating Alpha DaRT therapy in patients with recurrent glioblastoma.

The data capture patient outcomes through November 11, 2026.

Strong Tumor Response Rates

Clinicians have treated eight patients in the trial so far, and six have reached MRI response assessment. Under RANO criteria, all six evaluable patients achieved an objective response.

Five patients, or 83.3%, achieved a complete response with no measurable tumor remaining at the treated site. One patient, or 16.7%, achieved a partial response with a 58% reduction in tumor measurements.

All three patients from the initial May 2026 update now have confirmed complete responses after one patient converted from stable disease during longer follow-up.

Subsequent scans must still confirm the early responses in the three newest patients.

Trial Safety And Patient Survival

All eight treated patients remained alive as of November 11, 2026. Among the six assessed patients, median follow-up reached 6.9 months, and the group has not yet reached median overall survival.

Clinicians successfully deployed planned Alpha DaRT sources in 100% of treated patients, meeting feasibility goals. Researchers observed no unanticipated serious adverse events, and all patients recovered from side effects without lasting procedure-related symptoms.

One patient with a prior seizure history experienced a previously reported grade 3 seizure with Todd’s paralysis that resolved with steroids after a 48-hour hospital stay.

Ongoing Follow-Up And Imaging

No patient showed definitive recurrence inside the treated zone, though the first treated patient developed progression outside that area after roughly nine months and received further therapy.

Follow-up scans revealed asymptomatic necrosis or suspected necrosis near the treated site in four of six assessed patients.

Investigators are using additional imaging and potential biopsies to determine whether new enhancement in two patients indicates necrosis or tumor progression as enrollment toward 20 patients continues.

DRTS Price Action: Alpha Tau Medical shares were up 15.70% at $15.48 during premarket trading on Monday. The stock is trading near its 52-week high of $15.79, according to Benzinga Pro data.

Image via Shutterstock